Iranian Red Crescent Medical Journal (IRCMJ)

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

Journal Metrics

News

Author Guidelines

Article Processing Charge

Prediction Model for Disease Progression and Relevant Prognostic Factors in Hodgkin Patients: An Application of Frailty Multistate Model

Document Type : Research articles

Authors

1 Department of Biostatistics and Epidemiology, Faculty of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Research Center of Thalassemia and Hemoglobinopathy, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

3 1. Department of Biostatistics and Epidemiology, Faculty of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran 2. Research Center of Thalassemia and Hemoglobinopathy, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Abstract

Background: In clinical cancer studies, there has been a high tendency of searching for more specific and new prognostic factors in cancers in the last few years. This multistate study aimed to model the progression of Hodgkin's disease by accounting for individual effect (heterogeneity) using the joint and independent frailty models.
Method: After the utilization of the illness-death model, joint-modeling accounted for the dependency between relapse and death by considering the individual characteristics as a frailty term. Therefore, the effect of influential prognostic factors was evaluated on disease progression by frailty and joint-frailty multistate models.
Results: The individual predictions were determined using the frameworks of the both models. The model was applied to 389 Hodgkin lymphoma patients. Gender (male), age (over 55 years), and low level of hemoglobin (less than 10.5) were associated with an increased risk of death and relapse in patients. The likelihood cross-validation criterion was proposed to choose the joint frailty model as a better fitting model.
Conclusion: Multistate models were appropriate tools to study the whole event history of the subjects, which provided a deep insight into the dynamics of the disease. The problem of events-subjects dependency in the survival data was clarified using the multistate model. Therefore, the heterogeneity and dependency between the states led to more accurate estimations of the effects of the prognostic factors, thereby improving the predictions.

Keywords

References
  1. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011;117(16):4208-17. doi: 10.1182/blood-2010-09-288373. [PubMed: 21263152].
  2. Johnson P, McKenzie H. How I treat advanced classical Hodgkin lymphoma. Blood. 2015;125(11):1717-23. doi: 10.1182/blood-2014-09-551556. [PubMed: 25564404].
  3. Zare A, Mahmoodi M, Mohammad K, Zeraati H, Hosseini M, Holakouie-Naieni K. Assessing misspecification of individual homogeneity assumption in multi-state models based on asymptotic theory. J Biostat Epidemiol. 2015;1(3/4):70-9.
  4. Lokich JJ, Pinkus GS, Moloney WC. Hodgkin's disease in the elderly. Oncology. 1974;29(6):484-500. doi: 10.1159/000224931. [PubMed: 4140486].
  5. Boyle P, Levin B. World cancer report 2008. Geneva: IARC Press, International Agency for Research on Cancer; 2008. P. 15-25.
  6. Liquet B, Timsit JF, Rondeau V. Investigating hospital heterogeneity with a multi-state frailty model: application to nosocomial pneumonia disease in intensive care units. BMC Med Res Methodol. 2012;12:79. doi: 10.1186/1471-2288-12-79. [PubMed: 22702430].
  7. Rondeau V, Mathoulin-Pelissier S, Jacqmin-Gadda H, Brouste V, Soubeyran P. Joint frailty models for recurring events and death using maximum penalized likelihood estimation: application on cancer events. Biostatistics. 2007;8(4):708-21. doi: 10.1093/biostatistics/kxl043. [PubMed: 17267392].
  8. Rotolo F, Legrand C. Frailty multi-state models using maximum penalised partial likelihood estimation. Padova, Italy: University of Padova; 2019.
  9. Beyersmann J, Wolkewitz M, Allignol A, Grambauer N, Schumacher M. Application of multistate models in hospital epidemiology: advances and challenges. Biom J. 2011;53(2):332-50. doi: 10.1002/bimj.201000146. [PubMed: 21374697].
  10. Meier-Hirmer C, Schumacher M. Multi-state model for studying an intermediate event using time-dependent covariates: application to breast cancer. BMC Med Res Methodol. 2013;13:80. doi: 10.1186/1471-2288-13-80. [PubMed: 23786493].
  11. Broët P, de la Rochefordière A, Scholl SM, Fourquet A, De Rycke Y, Pouillart P, et al. Analyzing prognostic factors in breast cancer using a multistate model. Breast Cancer Res Treat. 1999;54(1):83-9. doi: 10.1023/a:1006197524405. [PubMed: 10369084].
  12. Sutradhar R, Forbes S, Urbach DR, Paszat L, Rabeneck L, Baxter NN. Multistate models for comparing trends in hospitalizations among young adult survivors of colorectal cancer and matched controls. BMC Health Serv Res. 2012;12:353. doi: 10.1186/1472-6963-12-353. [PubMed: 23043307].
  13. Conlon AS, Taylor JM, Sargent DJ. Multi-state models for colon cancer recurrence and death with a cured fraction. Stat Med. 2014;33(10):1750-66. doi: 10.1002/sim.6056. [PubMed: 24307330].
  14. Rondeau V, Mauguen A, Laurent A, Berr C, Helmer C. Dynamic prediction models for clustered and interval-censored outcomes: investigating the intra-couple correlation in the risk of dementia. Stat Methods Med Res. 2017;26(5):2168-83. doi: 10.1177/0962280215594835. [PubMed: 26184832].
  15. Mauguen A, Rachet B, Mathoulin-Pélissier S, MacGrogan G, Laurent A, Rondeau V. Dynamic prediction of risk of death using history of cancer recurrences in joint frailty models. Stat Med. 2013;32(30):5366-80. doi: 10.1002/sim.5980. [PubMed: 24030899].
  16. Rondeau V, Mazroui Y, Gonzalez JR. Frailtypack: an R package for the analysis of correlated survival data with frailty models using penalized likelihood estimation or parametrical estimation. J Stat Softw. 2012;47(4):1-28.
  17. Parast L, Tian L, Cai T. Landmark estimation of survival and treatment effect in a randomized clinical trial. J Am Stat Assoc. 2014;109(505):384-94. doi: 10.1080/01621459.2013.842488. [PubMed: 24659838].
  18. Mazroui Y, Mathoulin-Pélissier S, Macgrogan G, Brouste V, Rondeau V. Multivariate frailty models for two types of recurrent events with a dependent terminal event: application to breast cancer data. Biom J. 2013;55(6):866-84. doi: 10.1002/bimj.201200196. [PubMed: 23929494].
  19. Putter H, van Houwelingen HC. Frailties in multi-state models: are they identifiable? Do we need them? Stat Methods Med Res. 2015;24(6):675-92. doi: 10.1177/0962280211424665. [PubMed: 22116343].
  20. !!! INVALID [A1] CITATION !!! [9, 10].
  21. Bierman PJ, Lynch JC, Bociek RG, Whalen VL, Kessinger A, Vose JM, et al. The international prognostic factors project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol. 2002;13(9):1370-7. doi: 10.1093/annonc/mdf228. [PubMed: 12196362].
  22. Smolewski P, Robak T, Krykowski E, Blasiñska-Morawiec M, Niewiadomska H, Pluzanska A, et al. Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res. 2000;6(3):1150-60. [PubMed: 10741746].
  23. Bierman PJ, Bagin RG, Jagannath S, Vose JM, Spitzer G, Kessinger A, et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol. 1993;4(9):767-73. doi: 10.1093/oxfordjournals.annonc.a058662. [PubMed: 8280658].
  24. Fermé C, Bastion Y, Brice P, Lederlin P, Diviné M, Gabarre J, et al. Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study. Cancer. 1997;80(6):1124-33. [PubMed: 9305714].
  25. Kılıçkap S, Barışta I, Ulger S, Celik I, Selek U, Yıldız F, et al. Clinical features and prognostic factors of Hodgkin's lymphoma: a single center experience. Balkan Med J. 2013;30(2):178-85. doi: 10.5152/balkanmedj.2012.110. [PubMed: 25207097].
  26. Balducci L, Phillips DM, Davis KM, Files JC, Khansur T, Hardy CL. Systemic treatment of cancer in the elderly. Arch Gerontol Geriatr. 1988;7(2):119-50. doi: 10.1016/0167-4943(88)90026-x. [PubMed: 3046534].
  27. Peterson BA, Pajak TF, Cooper MR, Nissen NI, Glidewell OJ, Holland JF, et al. Effect of age on therapeutic response and survival in advanced Hodgkin's disease. Cancer Treat Rep. 1982;66(4):889-98. [PubMed: 7042088].
  28. Austin-Seymour MM, Hoppe RT, Cox RS, Rosenberg SA, Kaplan HS. Hodgkin's disease in patients over sixty years old. Ann Intern Med. 1984;100(1):13-8. doi: 10.7326/0003-4819-100-1-13. [PubMed: 6691638].
  29. Specht L, Nissen NI. Hodgkin's disease and age. Eur J Haematol. 1989;43(2):127-35. [PubMed: 2792320].
  30. Davis S, Dahlberg S, Myers MH, Chen A, Steinhorn SC. Hodgkin's disease in the United States: a comparison of patient characteristics and survival in the Centralized Cancer Patient Data System and the Surveillance, Epidemiology, and End Results Program. J Natl Cancer Inst. 1987;78(3):471-8. [PubMed: 3469461].
  31. Sutcliffe SB, Wrigley PF, Peto J, Lister TA, Stansfeld AG, Whitehouse JM, et al. MVPP chemotherapy regimen for advanced Hodgkin's disease. Br Med J. 1978;1(6114):679-83. doi: 10.1136/bmj.1.6114.679. [PubMed: 630293].
  32. Vaughan Hudson B, MacLennan KA, Easterling MJ, Jelliffe AM, Haybittle JL, Vaughan Hudson G. The prognostic significance of age in Hodgkin's disease: examination of 1500 patients (BNLI report no. 23). Clin Radiol. 1983;34(5):503-6. doi: 10.1016/s0009-9260(83)80150-0. [PubMed: 6617081].
  33. Gobbi PG, Comelli M, Grignani GE, Pieresca C, Bertoloni D, Ascari E. Estimate of expected survival at diagnosis in Hodgkin's disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin's Disease (IDHD). Haematologica. 1994;79(3):241-55. [PubMed: 7926973].
  34. Haybittle JL, Hayhoe FG, Easterling MJ, Jelliffe AM, Bennett MH, Vaughan Hudson G, et al. Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index. Lancet. 1985;1(8435):967-72. doi: 10.1016/s0140-6736(85)91736-2. [PubMed: 2859421].
  35. Massini G, Siemer D, Hohaus S. EBV in Hodgkin lymphoma. Mediterr J Hematol Infect Dis. 2009;1(2):e2009013. doi: 10.4084/MJHID.2009.013. [PubMed: 21416003].
  36. Jeffery GM, Colls BM, Robinson BA, Fitzharris BM, Atkinson CH. A risk factor for relapse in Hodgkin's disease: female gender? Hematol Oncol. 1989;7(5):345-53. doi: 10.1002/hon.2900070503. [PubMed: 2767620].
  37. Klimm B, Reineke T, Haverkamp H, Behringer K, Eich HT, Josting A, et al. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. J Clin Oncol. 2005;23(31):8003-11. doi: 10.1200/JCO.2005.205.60. [PubMed: 16204002].
  38. Gobbi PG, Zinzani PL, Broglia C, Comelli M, Magagnoli M, Federico M, et al. Comparison of prognostic models in patients with advanced Hodgkin disease. Promising results from integration of the best three systems. Cancer. 2001;91(8):1467-78. doi: 10.1002/1097-0142(20010415)91:8<1467::aid-cncr1154>3.0.co;2-a. [PubMed: 11301394].
  39. Connors JM. Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma. Blood. 2015;125(11):1693-702. doi: 10.1182/blood-2014-07-537480. [PubMed: 25575542].
  40. Löffler M, Dixon DO, Swindell R. Prognostic factors of stage III and IV Hodgkin's disease. Treatment strategy in Hodgkin’s disease. Montrouge: John Libbey Eurotext; 1990. P. 89-104.
  41. Proctor SJ, Taylor P, Donnan P, Boys R, Lennard A, Prescott RJ. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Eur J Cancer. 1991;27(5):624-9. doi: 10.1016/0277-5379(91)90231-2. [PubMed: 1828974].
  42. Hasenclever D, Schmitz N, Diehl V. Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin's disease? German Hodgkin's Lymphoma Study Group (GHSG). Leuk Lymphoma. 1995;15(Suppl 1):47-9. doi: 10.3109/10428199509052706. [PubMed: 7767261].
  43. MacLennan KA, Vaughan Hudson B, Easterling MJ, Jelliffe AM, Vaughan Hudson G, Haybittle JL. The presentation haemoglobin level in 1103 patients with Hodgkin's disease (BNLI report no. 21). Clin Radiol. 1983;34(5):491-5. doi: 10.1016/s0009-9260(83)80146-9. [PubMed: 6617079].
  44. Cuccaro A, Bartolomei F, Cupelli E, Galli E, Giachelia M, Hohaus S. Prognostic factors in hodgkin lymphoma. Mediterr J Hematol Infect Dis. 2014;6(1):e2014053. doi: 10.4084/MJHID.2014.053. [PubMed: 25045461].
  45. Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. International prognostic score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. J Clin Oncol. 2012;30(27):3383-8. doi: 10.1200/JCO.2011.41.0910. [PubMed: 22869887].

Iranian Red Crescent Medical Journal (IRCMJ)
Volume 23, Issue 3 - Serial Number 3
2021
Files
History
  • Receive Date: 06 September 2020
  • Revise Date: 26 May 2024
  • Accept Date: 27 January 2024
  • First Publish Date: 27 January 2024
  • Publish Date: 01 March 2021
Share
How to cite
Statistics